GLP-1 drugs trim waists and testosterone in PCOS

GLP-1 receptor agonists are well established for promoting weight loss in people with diabetes and obesity, but their role in polycystic ovary syndrome has remained unclear. PCOS involves more than weight: hyperinsulinism and hyperandrogenism, meaning excess insulin and elevated male-pattern hormones, drive many of its symptoms. Whether drugs like semaglutide and liraglutide can shift those hormonal markers, rather than just the number on the scale, is an understudied question. This meta-analysis pooled the available placebo-controlled trials in women with PCOS living with obesity to find out.

The researchers systematically searched PubMed, Cochrane Central, Scopus and Embase for randomised controlled trials comparing GLP-1 receptor agonists with placebo in women diagnosed with PCOS under the Rotterdam Criteria. Four trials with 176 participants qualified. Liraglutide was used in 103 participants (58%) and semaglutide in 23 (13%). The primary outcomes were body mass index, triglycerides, waist circumference, total testosterone, total cholesterol and HOMA-IR, a standard score of insulin resistance, pooled as mean differences using a random-effects model.

GLP-1 drugs beat placebo on several fronts: waist circumference fell by 5.16 cm, BMI by 2.42 points, serum triglycerides by 0.20, and total testosterone also dropped significantly. Two markers did not move: total cholesterol showed no significant difference, and neither did HOMA-IR, the insulin resistance score, which is notable given that insulin resistance is central to PCOS. Safety information was available for 112 patients, of whom 49 experienced light side effects such as nausea and abdominal pain, with no serious harms reported in the abstract.

This extends the well-documented weight loss effects of GLP-1 drugs into a population where the evidence has been sparse, and adds a hormonal signal, the fall in total testosterone, that matters specifically for PCOS. The null result on insulin resistance complicates the picture, since improving insulin sensitivity is a key treatment goal in this condition. With only four trials and 176 women, every estimate here is provisional, and the mix of different drugs and doses leaves open which agent, at which dose, works best for PCOS specifically.

For women with PCOS who are following the GLP-1 story, this is early evidence that the drugs' benefits may extend beyond weight into the hormonal features of the condition, particularly testosterone levels, waist size and triglycerides. It is equally a reason for measured expectations: the insulin resistance score did not improve significantly, cholesterol was unchanged, and mild stomach side effects were common among those with safety data. The authors frame GLP-1 drugs as a favourable option for managing PCOS symptoms in women living with obesity, while the small evidence base keeps that verdict provisional.